Thermo Fisher Scientific Inc. $TMO Shares Acquired by Artemis Investment Management LLP

Artemis Investment Management LLP increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 105.5% in the third quarter, Holdings Channel reports. The institutional investor owned 84,793 shares of the medical research company’s stock after buying an additional 43,523 shares during the period. Artemis Investment Management LLP’s holdings in Thermo Fisher Scientific were worth $57,240,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in TMO. Legacy Wealth Managment LLC ID increased its position in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares in the last quarter. Kilter Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $25,000. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth approximately $26,000. MBM Wealth Consultants LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $29,000. Finally, Pingora Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity

In related news, VP Lisa Britt sold 11,440 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 73,768 shares of company stock valued at $44,122,820. Company insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TMO. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 1st. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 28th. BMO Capital Markets cut shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Finally, Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research note on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $635.55.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded down $17.54 during trading hours on Thursday, reaching $644.52. 1,426,760 shares of the stock traded hands, compared to its average volume of 2,247,260. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $694.33. The company has a market capitalization of $238.31 billion, a P/E ratio of 34.67, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. The company’s 50-day simple moving average is $624.23 and its two-hundred day simple moving average is $539.29. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the company earned $4.28 EPS. The firm’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.